HTG Molecular Diagnostics Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DL… Read more
HTG Molecular Diagnostics Inc. (HTGMQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2023: -9.196x
Based on the latest financial reports, HTG Molecular Diagnostics Inc. (HTGMQ) has a cash flow conversion efficiency ratio of -9.196x as of March 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.36 Million) by net assets ($474.50K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HTG Molecular Diagnostics Inc. - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how HTG Molecular Diagnostics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
HTG Molecular Diagnostics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HTG Molecular Diagnostics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
0.000x |
|
AJA Health and Wellness Inc.
V:AJA
|
N/A |
|
AGILE PROP HOLD (A8P.SG)
STU:A8P
|
N/A |
|
iExalt Inc
OTCGREY:IEXA
|
0.378x |
|
PT Trimitra Trans Persada Tbk
JK:BLOG
|
N/A |
|
Sabien Technology Group Plc
LSE:SNT
|
-0.634x |
|
ACME Printing and Packaging PLC
CM:ACMEN0000
|
N/A |
|
El Orouba Securities Brokerage
EGX:EOSB
|
N/A |
Annual Cash Flow Conversion Efficiency for HTG Molecular Diagnostics Inc. (2012–2022)
The table below shows the annual cash flow conversion efficiency of HTG Molecular Diagnostics Inc. from 2012 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $5.39 Million | $-18.41 Million | -3.414x | -115.08% |
| 2021-12-31 | $10.40 Million | $-16.51 Million | -1.587x | -41.13% |
| 2020-12-31 | $14.48 Million | $-16.29 Million | -1.125x | -61.48% |
| 2019-12-31 | $23.97 Million | $-16.70 Million | -0.697x | -11.52% |
| 2018-12-31 | $21.09 Million | $-13.17 Million | -0.625x | -111.53% |
| 2017-12-31 | $-3.06 Million | $-16.57 Million | 5.417x | +36.25% |
| 2016-12-31 | $-5.59 Million | $-22.23 Million | 3.975x | +449.00% |
| 2015-12-31 | $16.89 Million | $-19.24 Million | -1.139x | -310.70% |
| 2014-12-31 | $-24.04 Million | $-13.00 Million | 0.541x | +2.65% |
| 2013-12-31 | $-22.45 Million | $-11.82 Million | 0.527x | +10.79% |
| 2012-12-31 | $-18.26 Million | $-8.68 Million | 0.475x | -- |